New hope for eye cancer: targeted drug combo shows promise in early trial

NCT ID NCT07247383

Ongoing Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tests a targeted cancer drug called orelabrutinib combined with either low-dose radiation or another drug (rituximab) in 39 people with a rare eye lymphoma (ocular adnexal MALT lymphoma). The goal is to see how well the combination shrinks tumors and how safe it is. Participants have early-stage disease and have not had prior treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Orelabrutinib (a targeted cancer drug) plus either low-dose radiation or rituximab (another cancer drug)
What this could lead to: If successful, this could offer a new, less toxic treatment option for a rare eye lymphoma, potentially improving tumor control without harsh side effects.
What could go wrong: This is a small, early-phase trial (39 people) with no control group, so results may not apply broadly. The combination may cause side effects or fail to shrink tumors in some patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA (MZL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Lymphoma, B-Cell, Marginal Zone marginal zone lymphoma ocular adnexal lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MARGINAL ZONE LYMPHOMA (MZL) MARGINAL ZONE LYMPHOMA OF OCULAR ADNEXAL

Contacts and locations

Locations

2ndAffiliated Hospital, School of Medicine, Zhejiang University, China

Hangzhou, Zhejiang, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.